Trial · NCT07602699
Multi-Site Trial of Tirzepatide for Smoking Cessation
NCT07602699, Phase 2, Recruiting, University of Southern California
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multi-Site Trial of Tirzepatide for Smoking Cessation. Trials, record NCT07602699. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07602699
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multi-Site Trial of Tirzepatide for Smoking Cessation
- NCT number
- NCT07602699
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 300 participants, estimated
- Lead sponsor
- University of Southern California
- Conditions
- Smoking Cessation, Smoking Behaviors
- Interventions
- Tirzepatide, Placebo
- First posted
- 2026-05-22
- Last updated
- 2026-07-17
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 7-day point prevalence abstinence | From baseline through 16 weeks of treatment (final assessment at Week 17 visit) and at 6 months after the target quit date (assessed at Week 27 visit) | Biochemically verified abstinence from cigarette smoking |
| Secondary | Cigarettes per day | From baseline through 16 weeks of treatment (final assessment at Week 17 visit) | |
| Secondary | Weekly cigarette craving | Baseline through 16 weeks of treatment (final assessment at Week 17 visit) | Cigarette craving in the past week will be measured using the craving scale of the Wisconsin Smoking Withdrawal Scale, containing 4 items, each scored on a scale of 1-4. Items are summed to generate a score. |
| Other | Current cigarette craving | Baseline through 16 weeks of treatment (final assessment at Week 17 visit) | Current cigarette craving will be measured with the Questionnaire on Smoking Urges-Brief, a 10-item scale with items, each scored on a 1-7 scale. Items are summed to generate a total score. |
| Other | Smoking withdrawal | Baseline through 16 weeks of treatment (final assessment at Week 17 visit) | Withdrawal symptoms are measured with the Wisconsin Smoking Withdrawal Scale (WSWS). The WSWS includes 28 items, each rated on a scale of 0-4. Items are summed to calculate the scale scores. |
| Other | Body weight | Treatment week 1 through treatment week 16 (final assessment at Week 17 visit) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01DA064384 | Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking Cessation | HENDERSHOT, CHRISTIAN S; KING, ANDREA C; MCKEE, SHERRY ANN; SCHACHT, JOSEPH P. | UNIVERSITY OF SOUTHERN CALIFORNIA | NATIONAL INSTITUTE ON DRUG ABUSE | 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07602699
GET https://conductscience.org/api/trials/v1/NCT07602699/registered